These findings underscore the prognostic value of both a serum biomarker (CEA) and metastatic pattern (particularly brain involvement), while also supporting the survival benefit of first‐line EGFR‐TKI therapy in patients with stage IV lung cancer. Here, EGFR is linked to lung cancer.